ES2153964T3 - Liberacion controlada de farmacos administrados por via sublingual o bucal. - Google Patents

Liberacion controlada de farmacos administrados por via sublingual o bucal.

Info

Publication number
ES2153964T3
ES2153964T3 ES96919399T ES96919399T ES2153964T3 ES 2153964 T3 ES2153964 T3 ES 2153964T3 ES 96919399 T ES96919399 T ES 96919399T ES 96919399 T ES96919399 T ES 96919399T ES 2153964 T3 ES2153964 T3 ES 2153964T3
Authority
ES
Spain
Prior art keywords
sublingual
oral
road
controlled release
drugs administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96919399T
Other languages
English (en)
Inventor
Ragab El-Rashidy
Bruce Ronsen
Emad Eldin Hassan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pentech Pharmaceuticals Inc
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2153964T3 publication Critical patent/ES2153964T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

UNA COMPOSICION QUE PROPORCIONA UNA LIBERACION RELATIVAMENTE LENTA DE FARMACOS HIDROSOLUBLES, TALES COMO LA APOMORFINA, PARA SU ADMINISTRACION POR VIA SUBLINGUAL O BUCAL.
ES96919399T 1995-06-13 1996-06-13 Liberacion controlada de farmacos administrados por via sublingual o bucal. Expired - Lifetime ES2153964T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/489,966 US5624677A (en) 1995-06-13 1995-06-13 Controlled release of drugs delivered by sublingual or buccal administration

Publications (1)

Publication Number Publication Date
ES2153964T3 true ES2153964T3 (es) 2001-03-16

Family

ID=23946020

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96919399T Expired - Lifetime ES2153964T3 (es) 1995-06-13 1996-06-13 Liberacion controlada de farmacos administrados por via sublingual o bucal.

Country Status (10)

Country Link
US (1) US5624677A (es)
EP (1) EP0833619B1 (es)
AT (1) ATE198269T1 (es)
AU (1) AU705488B2 (es)
DE (1) DE69611369T2 (es)
DK (1) DK0833619T3 (es)
ES (1) ES2153964T3 (es)
GR (1) GR3035548T3 (es)
PT (1) PT833619E (es)
WO (1) WO1996041619A1 (es)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
IN186245B (es) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US6495539B1 (en) 1998-02-19 2002-12-17 Washington University B-lactam-like chaperone inhibitors
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
US6011035A (en) 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
JP2002539165A (ja) * 1999-03-16 2002-11-19 ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド 舌下またはバッカル投与により送出されるシルデナフィルの制御放出
EA004101B1 (ru) * 1999-09-03 2003-12-25 Эли Лилли Энд Компани Применение селективных ингибиторов обратного захвата серотонина быстрого запуска для лечения половой дисфункции
US6841559B1 (en) 1999-11-19 2005-01-11 Washington University Of St. Louis Pyridinones to treat and prevent bacterial infections
BR0109515A (pt) 2000-04-07 2004-08-10 Tap Pharmaceutical Prod Inc Derivados da apomorfina e métodos para seu uso
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
JP2004520389A (ja) * 2001-02-08 2004-07-08 ファルマシア・コーポレーション 性的不全の治療のための早期効果発現薬剤
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US20060073174A1 (en) * 2001-08-16 2006-04-06 Access Pharmaceuticals, Inc. Adherent and erodible film to treat a moist surface of a body tissue
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
PL372290A1 (en) * 2002-02-07 2005-07-11 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7507760B2 (en) * 2004-01-22 2009-03-24 Neuromed Pharmaceuticals Ltd. N-type calcium channel blockers
WO2005102330A2 (en) * 2004-04-16 2005-11-03 Washingtion University Amino methylated 2-pyridinones
TR200701423T1 (tr) * 2004-09-09 2007-05-21 Bayer Animal Health Gmbh Farmasötik bileşim.
US20070020186A1 (en) * 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
ES2577514T3 (es) * 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
US9265732B2 (en) * 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
WO2007118323A1 (en) * 2006-04-17 2007-10-25 Neuromed Pharmaceuticals Ltd. Isoxazole derivatives as calcium channel blockers
EP2029597A4 (en) 2006-05-31 2011-11-23 Univ California purine analogs
US7956064B2 (en) * 2006-09-01 2011-06-07 Cylene Pharmaceuticals, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
US20100168103A1 (en) * 2006-09-14 2010-07-01 Neuromed Pharmaceuticals Ltd. Diaryl piperidine compounds as calcium channel blockers
CA2666275A1 (en) * 2006-10-13 2008-04-17 Neuromed Pharmaceuticals Ltd. Cyclopropyl-piperazine compounds as calcium channel blockers
US20090054333A1 (en) * 2006-10-17 2009-02-26 Antonio Giordano Peptide inhibitors of cyclin-dependent kinase activity and uses thereof
ES2552471T3 (es) 2007-02-07 2015-11-30 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
JP5454943B2 (ja) * 2007-04-12 2014-03-26 ジョイアント ファーマスーティカルズ、インク． 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
US20080318939A1 (en) * 2007-06-22 2008-12-25 Whitten Jeffrey P Methods for treating ophthalmic disorders
CN101801190A (zh) * 2007-06-22 2010-08-11 赛林药物股份有限公司 治疗异常细胞增殖性疾病的方法
WO2009097014A2 (en) * 2007-08-31 2009-08-06 Cylene Pharmaceuticals, Inc. Therapeutic kinase modulators
US8486928B2 (en) * 2007-11-14 2013-07-16 Galera Therapeutics Super-oxide dismutase mimetics
US20090155392A1 (en) * 2007-12-17 2009-06-18 Bret David Nelson Methods and Systems for Sublingual Guarana Administration
WO2009086170A1 (en) * 2007-12-21 2009-07-09 Joyant Pharmaceuticals, Inc. Diazonamide analogs with improved solubility
EA201001264A1 (ru) * 2008-02-07 2011-04-29 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
AU2009219154A1 (en) * 2008-02-29 2009-09-03 Cylene Pharmaceuticals, Inc. Protein kinase modulators
US20090270413A1 (en) * 2008-04-28 2009-10-29 Galemmo Jr Robert Di-t-butylphenyl piperazines as calcium channel blockers
CA2722704A1 (en) * 2008-04-28 2009-11-05 Zalicus Pharmaceuticals Ltd. Cyclylamine derivatives as calcium channel blockers
WO2009132452A1 (en) * 2008-04-28 2009-11-05 Neuromed Pharmaceuticals Ltd. Diaryl-cyclylalkyl derivatives as calcium channel blockers
AU2009243056B2 (en) * 2008-04-29 2015-05-14 Joyant Pharmaceuticals, Inc. Indoline anti-cancer agents
WO2009143485A1 (en) * 2008-05-22 2009-11-26 Joyant Pharmaceuticals, Inc. Diazonamide analogs
US8377968B2 (en) 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
US9241896B2 (en) 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
CN102596969A (zh) 2009-08-26 2012-07-18 赛林药物股份有限公司 用作蛋白激酶调节剂的稠合喹啉类化合物
EP2784076A1 (en) 2009-10-28 2014-10-01 Joyant Pharmaceuticals, Inc. Dimeric SMAC mimetics
BR112012012945A2 (pt) 2009-11-25 2020-12-29 Arisgen Sa Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
CN102762208A (zh) 2009-12-04 2012-10-31 赛林药物股份有限公司 作为ck2抑制剂的吡唑嘧啶和相关杂环
NZ603155A (en) 2010-04-30 2014-06-27 Telormedix Sa Phospholipid drug analogs
WO2011134669A1 (en) 2010-04-30 2011-11-03 Telormedix Sa Methods for inducing an immune response
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
CA2805222A1 (en) 2010-07-13 2012-01-19 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
US20120083473A1 (en) 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators
US20140031302A1 (en) 2010-10-22 2014-01-30 Universite De Strasbourg Pochoxime conjugates useful for the treatment of hsp90 related pathologies
NZ612686A (en) 2010-12-16 2015-11-27 Cynapsus Therapeutics Inc Sublingual films
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
EP2654726A1 (en) * 2011-03-08 2013-10-30 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
HRP20171930T1 (hr) 2011-04-22 2018-02-09 Joyant Pharmaceuticals, Inc. Analozi diazonamida
HK1201067A1 (en) 2011-10-24 2015-08-21 罕见病药物研发公司 Sialic acid analogs
EP2903987B1 (en) 2012-10-01 2017-09-20 Urogen Pharma Ltd. Phospholipid drug analogs
US20140335139A1 (en) 2013-05-13 2014-11-13 NeuOra Microceuticals, LLC Long lasting breath mint
CA2930410A1 (en) 2013-11-11 2015-05-14 Impax Laboratories, Inc. Rapidly disintegrating formulations and methods of use
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
CN107278151A (zh) 2014-12-15 2017-10-20 约翰霍普金斯大学 舒尼替尼制剂及其在治疗青光眼中的使用方法
US10533016B2 (en) 2015-01-09 2020-01-14 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
TW201629069A (zh) 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
JP7211706B2 (ja) 2015-04-21 2023-01-24 サノヴィオン ファーマシュティカルズ インコーポレーテッド 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法
US10385085B2 (en) 2015-09-14 2019-08-20 Ultragenyx Pharmaceutical Inc. Crystal forms of sialic acid or salt or solvate thereof
WO2017059207A1 (en) 2015-10-01 2017-04-06 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
CN108367079B (zh) 2015-11-12 2022-11-22 灰色视觉公司 用于治疗的聚集性微粒
US20190144503A1 (en) 2016-04-27 2019-05-16 Regents Of The University Of Minnesota Methods for the identification of bifunctional compounds
KR20230075528A (ko) 2016-05-03 2023-05-31 갈레라 랩스, 엘엘씨 암 치료를 위한 조합 요법
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
EP3554489A4 (en) 2016-12-15 2020-06-17 Evoke Pharma, Inc. TREATMENT FROM MODERATE TO HEAVY GASTROPARESIS
CA3056923A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
CA3057741A1 (en) 2017-03-28 2018-10-04 Pimera, Inc. Novel crystal forms of a pol1 inhibitor
US11160870B2 (en) 2017-05-10 2021-11-02 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
WO2019126344A1 (en) 2017-12-20 2019-06-27 Bellicum Pharmaceuticals, Inc. Multimeric piperidine derivatives
JP7614086B2 (ja) * 2018-07-27 2025-01-15 セリナ・セラピユーテイツクス・インコーポレーテツド カテコール化合物と水溶性ポリマーの切断可能なコンジュゲート及びそれらを使用する治療方法
CN114340670B (zh) 2019-07-11 2026-02-17 普拉克西斯精密药物股份有限公司 T-型钙通道调节剂的制剂及其使用方法
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
CN120699039A (zh) 2019-11-04 2025-09-26 锐新医药公司 Ras抑制剂
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CA3217393A1 (en) 2021-05-05 2022-11-10 Elena S. Koltun Ras inhibitors
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
JP2026504244A (ja) 2022-11-09 2026-02-04 レヴォリューション・メディスンズ，インコーポレイテッド 化合物、複合体、ならびにそれらの調製方法及びそれらの使用方法
EP4676601A1 (en) 2023-03-03 2026-01-14 Deliver Therapeutics, Inc. Protein kinase inhibitors and uses thereof
EP4676600A1 (en) 2023-03-03 2026-01-14 Deliver Therapeutics, Inc. Protein kinase inhibitors and uses thereof
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
KR20260005904A (ko) 2023-04-07 2026-01-12 레볼루션 메디슨즈, 인크. 매크로사이클릭 ras 억제제
CN121263418A (zh) 2023-04-07 2026-01-02 锐新医药公司 大环ras抑制剂
KR20250172857A (ko) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025213065A1 (en) 2024-04-05 2025-10-09 Revolution Medicines, Inc. Peptide conjugates
WO2025213185A1 (en) 2024-04-05 2025-10-09 Revolution Medicines, Inc. Peptide conjugates
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US3428728A (en) * 1965-10-21 1969-02-18 Hans Lowey Timed release sublingual medications
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
DE3338978A1 (de) * 1982-10-29 1984-05-03 Basf Ag, 6700 Ludwigshafen Verapamil und gallopamil und ihre physiologisch vertraeglichen salze zur resorptiven anwendung auf den schleimhaeuten des mundes, des nasen-rachen-raums und des rektums
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
JP3310982B2 (ja) * 1994-04-22 2002-08-05 ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド 男性の勃起機能不全を改善するための剤形及び方法

Also Published As

Publication number Publication date
DE69611369D1 (de) 2001-02-01
EP0833619A4 (en) 1998-12-30
DE69611369T2 (de) 2001-04-26
EP0833619B1 (en) 2000-12-27
PT833619E (pt) 2001-04-30
EP0833619A1 (en) 1998-04-08
AU705488B2 (en) 1999-05-20
AU6174996A (en) 1997-01-09
GR3035548T3 (en) 2001-06-29
DK0833619T3 (da) 2001-01-22
US5624677A (en) 1997-04-29
WO1996041619A1 (en) 1996-12-27
ATE198269T1 (de) 2001-01-15

Similar Documents

Publication Publication Date Title
ES2153964T3 (es) Liberacion controlada de farmacos administrados por via sublingual o bucal.
TW430562B (en) Controlled release of drugs delivered by sublingual or buccal administration
NZ527867A (en) Oral pharmaceutical composition of cefpodoxime proxetil
UA34428C2 (uk) Заміщені фенілімідазолідини, спосіб їх одержання, фармацевтична композиція, проміжні сполуки
BG104315A (en) Prostaglandine agonists and their application for the treatment of osteal diseases
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
BR9916835A (pt) Composição de galantamina de liberação controlada
ES2176296T3 (es) Composiciones farmaceuticas que permiten la liberacion prolongada de trimetacidina despues de la administracion por via oral.
SE9704546D0 (sv) Novel compounds
IL117091A0 (en) Methylphenyloxazolidinone derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
DK0717041T3 (da) Krystallinske paclitaxel-hydrater
BRPI0408895A (pt) formulações de cladribina para administração oral e transmucosal aperfeiçoada
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
BR0212931A (pt) Composição farmacêutica de liberação prolongada contendo metformina
ES2159362T3 (es) Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
BRPI0412239A (pt) sistemas emulsificantes contendo derivados de azetidina
AP2001002369A0 (en) Pharmaceutical complex.
DE69802943D1 (de) Arzneizubereitung zur verabreichung von thiocolchicosid durch die mundschleimhaut
PT1052995E (pt) Composicao farmaceutica para a administracao por via nasal de tiocolchicosido
UY26746A1 (es) Liberación controlada de fármacos administrados por via sublingual o bucal
AR023056A1 (es) Composiciones farmaceuticas basadas en alfa-ciclodextrina para la administracion por via oral de analogos de lh-rh
MX9606264A (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol como sustancias farmacologicas activas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 833619

Country of ref document: ES